Respiratory Medicine and Research呼吸医学与研究
Respiratory Medicine and Research(英文缩写 RESPIR MED RES-FRANC),ISSN 2590-0412,eISSN 2590-0412,中文译名:呼吸医学与研究 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
Respiratory Medicine and Research 最新收录文献
-
1. Differences in influenza and pneumococcal vaccination coverage according to chronic respiratory diseases during the COVID-19 pandemic in France: a nationwide cohort study using the French national health data system.
PMID:日期:2026-08-28Chronic respiratory diseases (CRDs) are major contributors to morbidity and mortality globally. Exacerbations, often triggered by pathogens including Streptococcus pneumoniae and influenza virus, significantly worsen outcomes. French and international guidelines recommend vaccination against pneumococcal disease and influenza for at-risk adults. Previous studies found low pneumococcal vaccine uptake in France and other countries. The COVARISQ-2 study reassessed pneumococcal and influenza vaccination coverage during the 2013-2020 period and the 2020-2021 season, respectively, aamong adults with CRDs in France using nationwide claims data. Retrospective cohort study using the French National Health Data System (SNDS), covering 99% of the population. Adults (≥18 years) with CRDs (COPD, lung cancer, interstitial lung disease, cystic fibrosis, non-CF bronchiectasis, pulmonary hypertension, severe asthma) alive at the end of 2020 were included. Complete primary pneumococcal vaccination was defined as a dispensing of PCV13 followed within 12 months by PPSV23 between January 1, 2013 and December 31, 2020. Recommended PPSV23 booster doses were not captured. Influenza vaccination was defined as at least one dispensing during the 2020-2021 season. Multivariate logistic regression identified factors associated with vaccination. Among 1991,052 patients (mean age 67.5 years; 46.2% women), complete primary pneumococcal vaccination between 2013 and 2020 was observed in 16.2% (range: 13.5% pulmonary hypertension to 24.9% non-CF bronchiectasis); influenza coverage was 56.8% (range: 55.9% interstitial lung disease to 66.6% non-CF bronchiectasis). Age >65 years predicted influenza vaccination (OR = 4.09, 95% CI: 4.07-4.12) but not pneumococcal vaccination which was associated with ≥3 comorbidities (OR = 1.37, 95% CI: 1.36-1.39) and more healthcare visits. Female sex slightly reduced influenza vaccination odds. Sensitivity analyses were consistent. Primary pneumococcal sequence completion among French adults with CRDs was only 16% for pneumococcal vaccination over the 2013-2020 period, and seasonal influenza coverage was 56.8% for the 2020-2021 season, which is below the EU target of 75%. Older age and comorbidities were associated with higher uptake for influenza but not pneumococcal vaccination. In this high-risk population, post-pandemic monitoring of vaccination uptake is needed as well as strategies such as simplified vaccination schedules, expanded vaccinator roles, and systematic integration of vaccination into care pathways to improve protection.
-
2. Non-invasive ventilation during severe asthma exacerbation: Physiological rationale, current evidence, and practical approach.
PMID:日期:2026-08-28Severe asthma exacerbation (SAE) is characterized by acute airflow obstruction, dynamic hyperinflation, and marked increases in inspiratory effort and work of breathing. Although pharmacological therapy remains the cornerstone of treatment, its effects on the mechanical consequences of severe airway obstruction may be delayed. During this interval, progressive respiratory muscle overload may contribute to worsening gas exchange, hemodynamic compromise, and, ultimately, the need for invasive mechanical ventilation. Non-invasive ventilation (NIV) has a strong physiological rationale in this setting. By partially counterbalancing intrinsic positive end-expiratory pressure, NIV may reduce inspiratory threshold load, unload the respiratory muscles, and transiently limit dynamic hyperinflation while pharmacological therapy takes effect. Small randomized and observational studies suggest that NIV may transiently improve respiratory distress and gas exchange in selected patients. However, the available evidence remains limited, heterogeneous, and highly susceptible to selection bias; therefore, NIV cannot currently be recommended routinely in SAE. This review summarizes the pathophysiological basis, available clinical evidence, and practical aspects of NIV use in SAE, with particular attention to patient selection, timing of initiation, ventilator settings, aerosol delivery, and monitoring.
-
3. One-year outcome after endobronchial valve treatment of chronic obstructive pulmonary disease - a nationwide real-life cohort study.
PMID:日期:2026-08-25The efficacy of endobronchial valve (EBV) treatment has been demonstrated in randomized controlled trials. However, real-life nationwide data from more heterogeneous patient populations remains limited. Therefore, this study aims to evaluate the one-year outcome of EBV treatment in a nationwide cohort study. In this nationwide cohort study, Danish patients treated with endobronchial valves from 2017-2024 were included. Outcomes, such as lung function, exercise capacity, and dyspnea, were assessed at 3 and 12 months, together with data on complications and mortality. Data was obtained from electronic medical records. A total of 232 patients were included in the study. Follow-up visits at 3 (1-5) and 12 (9-18) months were available for 189 and 165 patients, respectively. Nine patients died within the first year, and 37 patients underwent valve removal. Significant improvements from baseline were observed at both follow-up points in lung function (forced expiratory volume in 1 second +4.75%points & +3.43%points, residual volume -30.5%points & -27.7%points, total lung capacity -7.0%points & -5.7%points), physical ability (6-minute walk distance +30.6 m & +20.8 m), and dyspnea (Medical Research Council dyspnea scale -0.73 & -0.47). Responder rates declined over time, but 40-50% of patients maintained a clinically meaningful benefit at the 12-month visit. Revision bronchoscopies were performed in 44% of the patients. Endobronchial valve treatment is associated with statistically significant improvements in lung function, exercise capacity, and dyspnea at both 3 and 12 months, with considerable inter-individual variability.
-
4. External validation of the CAPAD score to predict the occurrence of clinically significant pneumothorax after CT-guided percutaneous transthoracic lung biopsy.
PMID:日期:2026-08-11The most common complication preventing outpatient management after percutaneous CT-guided lung biopsy (PTLB) is the occurrence of pneumothorax requiring drainage. We previously developed a pragmatic score to predict the risk of clinically relevant pneumothorax after PTLB (hereafter called the CAPAD score), to guide patient management. To externally validate the CAPAD score in an independent cohort, with a specific focus on its ability to rule out pneumothorax requiring drainage after PTLB. We retrospectively analysed a pre-existing institutional database of consecutive adult patients undergoing CT-guided PTLB at Bichat-Claude-Bernard University Hospital (Paris, France) between 1 January 2015 and 31 December 2017. The CAPAD score combines five variables: COPD, Anterior PTLB approach, more than one Pleural crossing, pneumothorax ≥10 mm on the end-of-procedure CT (post-procedural immediate pneumothorax), and skin-pleura Distance ≤30 mm, with a pre-specified cut-off of 73 points. The primary endpoint was the diagnostic performance of the score for post-PTLB pneumothorax on the 4-6 h control CXR and secondary endpoint was its performance for pneumothorax requiring drainage. The CAPAD score was computable in 313 of 474 patients. Pneumothorax occurred in 95 patients (30.4%), and 23 patients (7.3%) required drainage. At the pre-specified cut-off of 73, the score had a C-index of 0.77, a sensitivity of 75%, a specificity of 56%, a negative predictive value (NPV) of 84% and a positive predictive value of 43% for any post-PTLB pneumothorax. For pneumothorax requiring drainage, a score < 73 was associated with a 2.0% risk (3/147), corresponding to a NPV of 98%. Our pragmatic CAPAD score demonstrated a good prognostic performance for predicting the risk of post-procedural pneumothorax, achieve a NPV of 98% for pneumothorax requiring drainage.
-
5. Diffuse alveolar hemorrhage in primary antiphospholipid syndrome: A case series of six patients.
PMID:日期:2026-08-07Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder characterized by persistent antiphospholipid antibodies (aPLs). Diffuse alveolar hemorrhage (DAH) is a rare but severe microvascular manifestation of APS associated with high morbidity and mortality. We retrospectively analyzed six consecutive patients with primary APS complicated by DAH who had been followed at our institution between 2018 and 2025. Clinical presentation, laboratory and radiological findings, treatment strategies, and outcomes were evaluated. Median age was 37.5 years (female:male 4:2). DAH was confirmed by bronchoscopy in all patients; triple aPL positivity was present in all. Most patients required hospitalization for severe respiratory failure, and recurrent DAH was frequent. Two patients died: one from uncontrolled DAH complicated by invasive fungal infection, and the other from pulmonary embolism. Two patients had a milder chronic course with fluctuating HRCT infiltrates but no severe hypoxemia. All patients received high-dose glucocorticoids followed by maintenance immunosuppression with rituximab, usually combined with mycophenolate. Adjunctive therapies included plasma exchange, intravenous immunoglobulin, and eculizumab. Antibody titers remained persistently positive in all cases. APS-associated DAH is a life-threatening complication with frequent relapses and poor prognosis, particularly in patients with triple positivity and recurrent DAH. None of the patients achieved long-term remission, and all experienced disease progression despite aggressive immunosuppressive therapy. Early recognition, aggressive immunosuppression, and close monitoring are crucial, while novel therapeutic options are urgently needed.
-
6. Therapeutic bronchoscopy for pulmonary lymphoma: data from the EpiGETIF registry.
PMID:日期:2026-08-07Tracheobronchial lymphoma is a rare, life-threatening condition where chemo- or radiotherapy efficacy may be delayed. Therapeutic bronchoscopy (TB) may provide rapid airway stabilisation, but data on outcomes remain limited. We conducted a multicentre retrospective study of 32 patients undergoing TB (December 2018-June 2024). Clinical, radiological, and endoscopic variables were analysed using descriptive statistics and Kaplan-Meier curves. 32 patients were included (63% male, mean age 66 ± 21 years). 26 patients (83%) were treatment-naïve; 18 (56%) had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1. The most frequent presenting symptoms were dyspnoea (mean Borg score 6 ± 2.6) and cough (87%). 15 patients (47%) required oxygen therapy at baseline. Computed tomography (CT) showed airway obstruction in most patients; atelectasis occurred in 14%. Procedures lasted a mean of 57 ± 45 min; complete procedural success was achieved in 78% of cases. Mechanical debulking (66%) and stent placement (78%) were the most commonly applied interventions. Complications occurred in 22%, correlating significantly with pre-procedure oxygen therapy (p = 0.014). Clinical improvement occurred in 83%; the mean Borg score decreased from 6 ± 2.6 to 1.4 ± 1.3 (p < 0.01). Median survival was 462 days overall (556 days in treatment-naïve and 117 days in previously treated patients). Monthly mortality showed a significant decreasing trend over time (p = 0.0023). Patients with ECOG PS ≥ 2 had significantly lower survival compared with those with ECOG PS < 2 (p < 0.01). Most lymphomas were B-cell (85%), and bronchoscopy established the diagnosis in 96% of patients without prior histology. TB achieves high procedural success and provides meaningful clinical improvement in patients with tracheobronchial lymphoma. Patient outcomes are strongly influenced by baseline performance status and previous therapies. These results emphasise the importance of conducting prospective studies to more clearly define the role of bronchoscopy within the multidisciplinary management of this rare disease.
-
7. Diaphragm dysfunction in mechanically ventilated patients: Comparing volume and pressure modes.
7. 机械通气患者膈肌功能障碍：比较容量和压力模式PMID:日期:2026-08-06Diaphragm dysfunction (DD) is a common complication of mechanical ventilation and contributes to prolonged ventilation and weaning failure. Data comparing the effects of volume- and pressure-targeted ventilation modes on diaphragm function are limited. This study compared synchronized intermittent mandatory ventilation (SIMV) and bilevel positive airway pressure (BiPAP) using bedside ultrasonography. In this prospective study, 40 mechanically ventilated adults admitted to two ICUs were enrolled (20 SIMV, 20 BiPAP) according to routine practice. Diaphragm excursion (DE) and diaphragmatic thickening fraction (DTF) were measured within 24 h of ventilation initiation and daily for up to 7 days during standardized pressure support sessions. DD was defined as DE < 1.5 cm or DTF < 20%. Repeated-measures analysis evaluated changes over time and between groups. Both DE and DTF declined significantly over time in both groups (P < 0.001). No significant differences were observed between SIMV and BiPAP for DE (P = 0.73) or DTF (P = 0.40). DD occurred in 50-70% of patients based on DE and in 25-35% based on DTF, without significant intergroup differences. Duration of mechanical ventilation was similar (median 4 days; P = 0.543). Both ventilation modes were associated with progressive diaphragm dysfunction, with no significant advantage of either mode.
-
8. Pulmonary rehabilitation in COPD with suspected pulmonary hypertension: a step toward.
PMID:日期:2026-07-30该文献暂无摘要。